Antibe Therapeutics Reports Q3 2015 Interim Financial and Operating Results and Director Resignation
Feb 27, 2015
OTC Disclosure News Service
Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) filed its
financial and operating results today for the fiscal quarter ended
December 31, 2014. The Corporation’s unaudited Q3 2015 financial
statements and MDA are available on SEDAR.
The Company also announced that Jonathan Ross Goodman has resigned from
the Company’s Board of Directors, effective today. Mr. Goodman has been
a Director since June 2013. Samira Sakhia will replace Mr. Goodman as
chair of the Audit Committee.
Mr. Goodman stated, “It has been a pleasure working with Antibe’s
management and Board; they are an extremely talented group. My duties at
Knight Therapeutics are simply too great to continue these additional
responsibilities. I look forward to remaining connected with the team.”
“Antibe’s management and shareholders would like to thank Jonathan for
his contributions to the company, the Board, and its shareholders. We
look forward to maintaining a close working relationship with Jonathan
and his business enterprises, and are grateful that he has offered
continued assistance.” said Walt Macnee, Chairman of Antibe’s Board of
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s lead
drug ATB-346 targets the global need for a safer non-steroidal
anti-inflammatory drug (NSAID) for chronic pain and inflammation.
ATB-352, the second drug in Antibe’s pipeline, targets the urgent global
need for a safer analgesic for severe acute pain.
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright © 2015 Businesswire. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.